Evidence map›Paper›PMID 37218597›Full record

ArticleRenal failure2023

Periosteum-derived mesenchymal stem cell alleviates renal fibrosis through mTOR-mediated Treg differentiation.

Yongsheng Luo, Kuanxin Zhang, Jiaheng Wu, Hao Zeng, Juntao Chen, Pingbao Zhang, Jingjing Guo, Cuidi Xu, Xinhao Niu, Yin Celeste Cheuk and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Yongsheng LuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Kuanxin ZhangDepartment of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiaheng WuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Hao ZengShanghai Medical College, Fudan University, Shanghai, China.
Juntao ChenDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Pingbao ZhangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingjing GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Cuidi XuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xinhao NiuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yin Celeste CheukDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shihao XuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yirui CaoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yufeng ZhaoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Dong ZhuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xuanchuan WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ruiming RongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNShanghai Institute of Organic Chemistry · CNZhongshan Hospital · CNSun Yat-sen University · CNFirst Affiliated Hospital of Zhengzhou University · CNShanghai Medical College of Fudan University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMesenchymal stem cells (MSCs) are the hotspots of cellular therapy due to their low immunogenicity, potent immunoregulation, and unique renoprotection. The present study aimed to investigate the effects of periosteum-derived MSCs (PMSCs) in ischemia-reperfusion (IR)-mediated renal fibrosis.

methodsUsing cell proliferation assay, flow cytometry, immunofluorescence, and histologic analysis, the differences in cell characteristics, immunoregulation, and renoprotection of PMSCs were compared to the bone marrow-derived MSCs (BMSCs), the most frequently studied stem cells in cellular therapy. In addition, the mechanism of PMSC renoprotection was investigated by 5' end of the RNA transcript sequencing (SMART-seq) and mTOR knockout mice.

resultsThe proliferation and differentiation capabilities of PMSCs were stronger than those of BMSCs. Compared with BMSCs, the PMSCs exerted a better effect on alleviating renal fibrosis. Meanwhile, the PMSCs more effectively promote Treg differentiation. Treg exhaustion experiment indicated that Tregs exerted an important effect on inhibiting renal inflammation and acted as a critical mediator in PMSC renoprotection. Additionally, SMART-seq results implied that the PMSCs promoted Treg differentiation, possibly via the mTOR pathway.

conclusionsCompared with BMSCs, the PMSCs exerted stronger immunoregulation and renoprotection that was mainly attributed to PMSC promotion for Treg differentiation by inhibiting the mTOR pathway.

Indexed as

Mesenchymal Stem CellsPeriosteumTOR Serine-Threonine KinasesAnimalsCell DifferentiationFibrosisMiceT-Lymphocytes, RegulatorymTOR protein, mouseTOR Serine-Threonine Kinasesischemia–reperfusionkidney transplantationmesenchymal stem cellmTORregulatory T cellsRenal fibrosis

Identifiers

PMID37218597
PMCPMC10208165
OpenAlexW4377564327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.